Published in Brain on November 10, 2009
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci (2011) 1.18
Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. Cell Death Dis (2013) 1.17
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Effect of spermidine on misfolding and interactions of alpha-synuclein. PLoS One (2012) 1.03
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla. Eur Radiol (2014) 0.95
Gaucher disease and parkinsonism, a molecular link theory. Mol Genet Metab (2010) 0.94
α-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol Chem (2011) 0.85
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One (2013) 0.84
Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener (2013) 0.84
Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport (2012) 0.83
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2011) 0.83
Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective. Exp Neurobiol (2013) 0.83
Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy. Front Neuroanat (2015) 0.82
Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism Relat Disord (2015) 0.81
Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol Dis (2010) 0.80
Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. Neurobiol Dis (2015) 0.79
Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation. Oncotarget (2015) 0.79
Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A (2016) 0.79
Models of multiple system atrophy. Curr Top Behav Neurosci (2015) 0.79
Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol Commun (2014) 0.79
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism Relat Disord (2015) 0.79
Multiple system atrophy: pathogenic mechanisms and biomarkers. J Neural Transm (Vienna) (2016) 0.78
Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson's Disease: A Study on Substantia Nigra and Striatum. Front Aging Neurosci (2015) 0.78
Deregulation of subcellular biometal homeostasis through loss of the metal transporter, Zip7, in a childhood neurodegenerative disorder. Acta Neuropathol Commun (2014) 0.78
Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation. Front Cell Neurosci (2015) 0.77
Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy. Neurobiol Dis (2013) 0.77
Characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase early amyloid-like oligomers and their implication in α-synuclein aggregation. J Biol Chem (2011) 0.76
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains. J Vis Exp (2016) 0.76
Novel therapeutic approaches in multiple system atrophy. Clin Auton Res (2014) 0.76
Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of Caenorhabditis elegans, a Potential Etiology of Parkinson's Disease. Front Nutr (2016) 0.75
Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. Front Neuroanat (2017) 0.75
Alpha-synuclein modulates dopamine neurotransmission. J Chem Neuroanat (2016) 0.75
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. Parkinsonism Relat Disord (2016) 0.75
Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice. J Addict Prev (2015) 0.75
A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Mol Neurodegener (2016) 0.75
Animal modeling an oligodendrogliopathy - multiple system atrophy. Acta Neuropathol Commun (2016) 0.75
Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci Rep (2017) 0.75
Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. Mol Neurobiol (2016) 0.75
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A (2006) 3.30
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A (2005) 2.69
Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology (2004) 2.18
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc (2003) 2.05
The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J Biol Chem (2004) 1.97
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J Biol Chem (2003) 1.83
Current concepts in the diagnosis and management of Parkinson's disease. CMAJ (2003) 1.83
Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.77
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord (2013) 1.64
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord (2012) 1.54
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Mortality in Parkinson's disease. Mov Disord (2010) 1.51
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem (2007) 1.46
Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord (2012) 1.44
Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism. J Neurochem (2013) 1.43
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys (2005) 1.42
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Mitochondria in Alzheimer's disease. Int Rev Neurobiol (2002) 1.40
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Functional analysis of NBC1 mutants associated with proximal renal tubular acidosis and ocular abnormalities. J Am Soc Nephrol (2005) 1.31
Why is parkinsonism not a feature of human methamphetamine users? Brain (2003) 1.29
Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem (2003) 1.28
Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend (2011) 1.25
Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol (2005) 1.23
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem (2005) 1.22
Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord (2010) 1.20
Mutational and functional analysis of SLC4A4 in a patient with proximal renal tubular acidosis. Pflugers Arch (2004) 1.19
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
Genotypic and phenotypic characterization of methicillin-susceptible Staphylococcus aureus isolates misidentified as methicillin-resistant Staphylococcus aureus by the BD GeneOhm MRSA assay. J Clin Microbiol (2011) 1.17
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther (2004) 1.16
The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction (2013) 1.15
Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proc Natl Acad Sci U S A (2010) 1.14
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2013) 1.12
Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol (2005) 1.11
FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov Disord (2009) 1.10
Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry (2012) 1.09
Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) (2008) 1.09
A mild form of adult-onset opsoclonus-myoclonus syndrome associated with antiglutamate receptor antibodies. JAMA Neurol (2013) 1.07
Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther (2006) 1.07
Defective dentate nucleus GABA receptors in essential tremor. Brain (2011) 1.07
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord (2005) 1.05
Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse (2004) 1.05
Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect Immun (2007) 1.03
Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet (2007) 1.03
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain (2004) 1.02
Retinal tau pathology in human glaucomas. Can J Ophthalmol (2008) 1.02
STX6 rs1411478 is not associated with increased risk of Parkinson's disease. Parkinsonism Relat Disord (2013) 1.01
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
Physical activity and the presence and extent of calcified coronary atherosclerosis. Med Sci Sports Exerc (2002) 1.01
Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology (2008) 1.01
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord (2002) 1.00
CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway. J Biol Chem (2006) 0.99
Moraxella catarrhalis binding to host cellular receptors is mediated by sequence-specific determinants not conserved among all UspA1 protein variants. Infect Immun (2008) 0.99
Parkinson's disease, stroke, and related epidemiology. Mov Disord (2005) 0.98
Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother (2007) 0.98
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Local unfolding of Cu, Zn superoxide dismutase monomer determines the morphology of fibrillar aggregates. J Mol Biol (2011) 0.96
Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse (2008) 0.96
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD. PLoS Curr (2011) 0.96
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
Metastatic PEComa to the brain. Acta Neuropathol (2006) 0.95
Clinical-pathological study of levodopa complications. Mov Disord (2002) 0.94
Disulfide scrambling describes the oligomer formation of superoxide dismutase (SOD1) proteins in the familial form of amyotrophic lateral sclerosis. J Biol Chem (2012) 0.94
Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. J Magn Reson Imaging (2010) 0.94